Joanne Hama

Array ( [id] => 19641417 [patent_doc_number] => 20240415937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => THEOPHYLLINE-LOADED COLLAGEN NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 18/210873 [patent_app_country] => US [patent_app_date] => 2023-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18210873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922991 [patent_doc_number] => 20240025995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => DUAL TARGETED IMMUNE REGULATING COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/334748 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324734 [patent_doc_number] => 20230122862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => TREATMENT OF IGE-MEDIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/964101 [patent_app_country] => US [patent_app_date] => 2022-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18279125 [patent_doc_number] => 20230094597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH EXCESSIVE OSTEOCLAST ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/934937 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18264605 [patent_doc_number] => 20230085847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/933133 [patent_app_country] => US [patent_app_date] => 2022-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281519 [patent_doc_number] => 20230096991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => METHOD OF USING PEGYLATED INTERFERON-ALPHA [patent_app_type] => utility [patent_app_number] => 17/897906 [patent_app_country] => US [patent_app_date] => 2022-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17897906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18094637 [patent_doc_number] => 20220412978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => USE OF CIRCULATING INTERLEUKIN-18 FOR PROGNOSTICATING AND TREATING RECURRENCE IN EARLY STAGE NON-SMALL CELL LUNG CANCER [patent_app_type] => utility [patent_app_number] => 17/808379 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18162123 [patent_doc_number] => 20230028715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => IL-31 MODULATORS FOR TREATING FXR-INDUCED PRURITIS [patent_app_type] => utility [patent_app_number] => 17/843232 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142578 [patent_doc_number] => 20230016422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ENGINEERED CELLS WITH IMPROVED PROTECTION FROM NATURAL KILLER CELL KILLING [patent_app_type] => utility [patent_app_number] => 17/830273 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981219 [patent_doc_number] => 20220347255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF HEREDITARY CYSTATIN C AMYLOID ANGIOPATHY (HCCAA) AND OTHER NEURODEGENERATIVE DISORDERS ASSOCIATED WITH ABERRANT AMYLOID DEPOSITS [patent_app_type] => utility [patent_app_number] => 17/749482 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020669 [patent_doc_number] => 20220372168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/735510 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805924 [patent_doc_number] => 20220257759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => TREATMENT OF SARCOMA USING IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 17/674371 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533694 [patent_doc_number] => 20220112303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => ANTI-CD24 ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/560582 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593453 [patent_doc_number] => 20220143026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/525731 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480691 [patent_doc_number] => 20220088195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => Prevention or mitigation of T-cell bispecific antibody-related adverse effects [patent_app_type] => utility [patent_app_number] => 17/448729 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17448729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473964 [patent_doc_number] => 20220081468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => SIZE EXCLUSION CHROMATOGRAPHY UTILIZING LOW CONCENTRATION AMINO ACIDS IN SIZE EXCLUSION CHROMATOGRAPHY MOBILE PHASE [patent_app_type] => utility [patent_app_number] => 17/477331 [patent_app_country] => US [patent_app_date] => 2021-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460337 [patent_doc_number] => 20220073642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => METHODS OF USING SURUFATINIB IN TREATING ADVANCED PANCREATIC AND EXTRA-PANCREATIC NEUROENDOCRINE TUMORS [patent_app_type] => utility [patent_app_number] => 17/467714 [patent_app_country] => US [patent_app_date] => 2021-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208549 [patent_doc_number] => 20230054807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => NEUTRALIZING MONO-SPECIFIC IgY ANTIBODIES TO INHIBIT OR TREAT SARS-COV-2 CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/387218 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18022040 [patent_doc_number] => 20220373539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/328816 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274497 [patent_doc_number] => 20210380695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => STING AGONIST COMBINATION TREATMENTS WITH IMMUNE CHECKPOINT INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/322827 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322827 [rel_patent_id] =>[rel_patent_doc_number] =>)